Sunil Anklekar’s commentary on the current topics in radiodiagnostic and radiotherapeutic nuclear medicines from a chemist’s perspective. This is an independent blog, and all opinions expressed are his own. The blog contents are for informational purpose only and should not be taken as a professional advice. For questions or comments on blogs, please email him at pharmafronts.author@gmail.com
Comparison of Cu-64, Ga-68 and F-18 PET imaging tracers
Cu-64, Ga-68, and F-18 radioisotopes are used in majority of the targeted PET radiotracers, and each offers trade-offs between image resolution, logistical convenience, cost and diagnostic versatility. The table below compares few important imaging parameters of these radiotracers. Table 1: Comparison of imaging parameters of Cu-64, Ga-68 and F-18 radiotracers Parameter Copper-64 Gallium-68 Fluorine-18 Half-life
Lu-177 radiotherapy competitive landscape
The field of targeted nuclear medicine is rapidly evolving as new players and innovative therapies enter the space. Two Lu-177 targeted radiotherapies are currently marketed from Novartis, for Prostate Cancer (Pluvicto), and Neuroendocrine Tumors, NETs, (Lutathera). These registered a combined revenue of USD 2.7B in 2025. The Lu-177 market is undergoing rapid evolution and growth
ITM’s NDA Accepted for Lu-177 GEP-NET Drug ITM-11
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Edotreotide is a synthetic form of somatostatin hormone and binds with high affinity to somatostatin receptors (SSTRs) expressed on tumor cells,
F-18 Flurcardo (Flurpiridaz), a Breakthrough PET Imaging for CAD
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating CAD, guiding treatment decisions, and identifying risk level. While SPECT agents like Tc-99m ( e.g. Sestamibi) have been in use for a long time, PET
Nuclear Medicine Imaging Stocks: Price Dip Analysis
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings, Telix Pharmaceuticals, and Clarity Pharmaceuticals have taken a hit, but beneath the surface, pipeline progress remains strong. For investors with a long-term horizon, this valuation
Comparison of Cu-64, Ga-68 and F-18 PET imaging tracers
Cu-64, Ga-68, and F-18 radioisotopes are used in majority of the targeted PET radiotracers, and each offers trade-offs between image resolution, logistical convenience, cost and diagnostic versatility. The table below compares few important imaging parameters of these radiotracers. Table 1: Comparison of imaging parameters of Cu-64, Ga-68 and F-18 radiotracers Parameter Copper-64 Gallium-68 Fluorine-18 Half-life
Lu-177 radiotherapy competitive landscape
The field of targeted nuclear medicine is rapidly evolving as new players and innovative therapies enter the space. Two Lu-177 targeted radiotherapies are currently marketed from Novartis, for Prostate Cancer (Pluvicto), and Neuroendocrine Tumors, NETs, (Lutathera). These registered a combined revenue of USD 2.7B in 2025. The Lu-177 market is undergoing rapid evolution and growth
ITM’s NDA Accepted for Lu-177 GEP-NET Drug ITM-11
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Edotreotide is a synthetic form of somatostatin hormone and binds with high affinity to somatostatin receptors (SSTRs) expressed on tumor cells,
F-18 Flurcardo (Flurpiridaz), a Breakthrough PET Imaging for CAD
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating CAD, guiding treatment decisions, and identifying risk level. While SPECT agents like Tc-99m ( e.g. Sestamibi) have been in use for a long time, PET
Nuclear Medicine Imaging Stocks: Price Dip Analysis
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings, Telix Pharmaceuticals, and Clarity Pharmaceuticals have taken a hit, but beneath the surface, pipeline progress remains strong. For investors with a long-term horizon, this valuation
Download
Complimentary eReport
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the free report.
Categories
Archives
Like to receive in-depth analysis on radiopharmaceuticals straight to your inbox?
(Emails are kept strictly confidential)